Hence, it can be concluded that wild type CYP1A1, GSTP1 and null GSTM1 may be frequently linked to favorable outcome in patients treated with nilotinib as depicted by sustained deep molecular response in most CML patients. This evidence concerns the gene CYP1A1 and chronic myelogenous leukemia, BCR-ABL1 positive.